- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | Syra Health Wins $5.8 Mln Indiana Contract To Lead Child Mental Health Access Site | 1 | RTTNews | ||
| 20.05. | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Syra Health embarks on search for new CEO | 1 | Investing.com | ||
| 20.05. | Syra Health beginnt Suche nach neuem CEO | 2 | Investing.com Deutsch | ||
| 20.05. | Syra Health Board Begins CEO Search to Drive Growth | 80 | PR Newswire | CARMEL, Ind., May 20, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB: SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering... ► Artikel lesen | |
| SYRA HEALTH Aktie jetzt für 0€ handeln | |||||
| 09.05. | Syra Health GAAP EPS of -$0.04, revenue of $1.86M | 1 | Seeking Alpha | ||
| 08.05. | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Syra Health Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Syra Health Announces First Quarter Revenue of $1.9 Million, Up 6% YoY | 75 | PR Newswire | Revenue increase led by Population Health's 261% YoY Expansion
Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY
Continued Efficiency Gains... ► Artikel lesen | |
| 08.04. | Syra Health Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 01.04. | Syra Health to delist from Nasdaq Capital Market | 1 | Investing.com | ||
| 01.04. | Syra Health announces voluntary delisting from Nasdaq | 4 | Seeking Alpha | ||
| 01.04. | Syra Health kündigt Rückzug vom NASDAQ Capital Market an | 2 | Investing.com Deutsch | ||
| 01.04. | Syra Health Announces Voluntary Delisting from the Nasdaq Capital Market | 88 | PR Newswire | CARMEL, Ind., April 1, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering... ► Artikel lesen | |
| 13.03. | Syra Health sichert Vertragsverlängerung im Wert von 660.000 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.03. | Syra Health secures $660,000 population health contract extension | 1 | Seeking Alpha | ||
| 11.03. | Syra Health Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Syra Health Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 11.03. | Syra Health Announces Full-Year Revenue of $8.0 Million, Up 45% YoY | 224 | PR Newswire | 2024 Population Health Revenue Acceleration to 132% YoY
Q4 2024 Net Losses Cut Nearly in Half Compared to Q4 2023, Highlighting Major Efficiency Gains
Continued... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,091 | -9,00 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,745 | +6,58 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
| PING AN HEALTHCARE | 0,976 | +2,93 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
| CO-DIAGNOSTICS | 0,238 | -0,83 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 0,826 | -24,50 % | Cytosorbents Corp: CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR | PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions... ► Artikel lesen | |
| VERU | 0,500 | -0,60 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
| VOLITIONRX | 0,835 | 0,00 % | VolitionRx - Nu.Q advances in lung cancer management | Despite rapid advancements in cancer treatments, effective diagnostics for early screening and disease monitoring continue to be an unmet need. This is felt acutely in lung cancer, which is the leading... ► Artikel lesen | |
| EKSO BIONICS | 3,500 | +2,04 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
| IMUNON | 0,660 | -1,49 % | Imunon, Inc.: IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism... ► Artikel lesen | |
| BEYOND AIR | 0,153 | +2,68 % | Beyond Air-Aktionäre genehmigen Reverse-Aktiensplit | ||
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| NOVACYT | 0,492 | -1,30 % | Novacyt S.A. - Liquidity Agreement Monthly Update and TVR | ||
| AROVELLA THERAPEUTICS | 0,048 | 0,00 % | AROVELLA THERAPEUTICS LIMITED: Investor Presentation | ||
| MEMPHASYS | 0,002 | 0,00 % | MEMPHASYS LIMITED: CE Mark Lodged for Felix to Expand Global Access |
Das Unternehmen SYRA HEALTH CORP kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+0,48 %) liegt der Kurs bei 0,105 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYRA HEALTH CORP finden Sie auf Wallstreet Online.